SAN DIEGO, July 22, 2025 /PRNewswire/ -- Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, today announced that Geoffrey M. Glass has been appointed Chief Executive Officer (CEO), effective immediately. Mr. Glass has served as Chairman of the Board since 2022. Mr. Glass brings 30 years of experience in the life sciences industry within both innovators and services organizations, including substantial experience helping build the CDMO sector over the last 15 years. He previously served in executive roles at EY Consulting, Valeant Pharmaceuticals (now Bausch Health), Patheon (now Thermo Fisher Scientific), Sancilio Pharmaceuticals, and KINICITI. "Over the past few years Abzena has made incredible progress driving operational execution and strengthening our unique scientific capabilities, the combination of which has resulted in delighting many of our customers," said Mr. Glass.